Introduction {#section1-2058738419855567}
============

The anticancer activity of natural origin compounds has been recently focused by several studies.^[@bibr1-2058738419855567]^ In this context, plants used in the traditional medicine systems can be considered a valuable source of active compounds and important supplements for chemotherapy/treatment.^[@bibr2-2058738419855567]^

*Tinospora cordifolia* (Willd.) Miers is a widely used plant in Ayurvedic medicine, and it has been found endowed with several biological activities, including anticancer.^[@bibr3-2058738419855567]^

Among the secondary metabolites produced by this plant, isoquinoline alkaloids such as berberine (BBR) are claimed to be responsible for most of the beneficial effects attributed to the plant source. For instance, BBR has been used to treat different types of diarrhea,^[@bibr4-2058738419855567],[@bibr5-2058738419855567]^ and more recently, it has been found effective in the treatment of gastroenteritis, diabetes, hyperlipidemia, cardiovascular diseases, inflammatory conditions, hyperglycemia, and obesity.^[@bibr6-2058738419855567][@bibr7-2058738419855567][@bibr8-2058738419855567]--[@bibr9-2058738419855567]^ Moreover, this compound is endowed with anticancer activity on different cell lines.^[@bibr10-2058738419855567]^

In particular, regarding colon cancer cells, previous studies have shown the ability of BBR to induce cells death through different mechanisms, such as: activation of JNK/p38 apoptotic pathway, suppression of the Wnt/β-catenin signaling pathway and inhibition of growth/proliferation processes for example by inducing G1/S and G2/M cell cycle phase arrest.^[@bibr11-2058738419855567],[@bibr12-2058738419855567]^

Nevertheless, only few studies have been focused on the gene expression effects of BBR in colon cancer cells. Specifically, Hu et al.^[@bibr13-2058738419855567]^ reported a strong dose-dependent antiproliferative BBR activity on human colon cancer cells (HT-29), together with a gradual increasing of apoptotic cells proportion associated with a reduction of the expression of the survivin gene. Moreover, BBR has been reported to increase nonsteroidal anti-inflammatory drug-activated gene-1 (NAG-1) expression in HCT-116 and CaCo-2 cells. This gene has been investigated for its proapoptotic and anti-tumorigenic activity, since it is highly expressed in colon but significantly reduced in most human tumor biopsies.^[@bibr14-2058738419855567]^

With the aim to explore the potential chemopreventive activity of *T. cordifolia* and BBR, we tested their effect on the expression of a panel of genes selected because of their involvement in self-renewal, tumor progression, malignant transformation, cell mobility, and invasiveness.

This evaluation could lead to the identification of genes and cellular pathways involved in colon cancer facilitating the identification of possible therapeutic targets.

Materials and methods {#section2-2058738419855567}
=====================

Plant material and preparation of extracts {#section3-2058738419855567}
------------------------------------------

Dried and powdered *T. cordifolia* Willd. stem was supplied by Maharishi Ayurveda Product, Italy (Verona, Italy). The plant material was collected from Ram Bagh (Rajasthan, India) and authenticated by Dr M.R. Uniyal (Maharishi Ayurveda Product Ltd, Noida, India).

Extraction was performed by treating 300 g of plant with 2 L of MeOH/H~2~O (1:1) and sonication for 1 h. The extract was filtered on Büchner funnel and the solvents were evaporated under vacuum at 40°C. The procedure was repeated for three times, obtaining 28.4 g of crude extract.

BBR analysis {#section4-2058738419855567}
------------

*T. cordifolia* extract was preliminarily analyzed by ultraviolet (UV) spectrophotometry (Jasco, Tokyo, Japan) and ultraviolet high-powered liquid chromatography (HPLC-UV; Jasco, Tokyo, Japan). BBR UV spectrum shows the most intense absorbance at the wavelengths of 228, 266, and 342 nm, among which the work wavelength chosen for HPLC-UV analysis was 266 nm.

The screening data obtained by UV and HPLC-UV were subsequently confirmed by MS and LC-MS (Waters, Milford, USA). The triple quadrupole mass analyzer was operating in positive mode electrospray ionization (ESI+), and acquisitions were performed in multiple reaction monitoring (MRM).

Both HPLC-UV and liquid chromatography--mass spectrometry (LC-MS) methods were original, developed, and validated *ad hoc* for the application to *T. cordifolia* extract.

*T. cordifolia* extract was subjected to standardization, using BBR pure powder as a reference standard (Sigma-Aldrich, Inc, St. Louis, MO, USA).

The title of BBR in the extract of *T. cordifolia* was 120 mg/g dry extract.

Cell culture {#section5-2058738419855567}
------------

Human colon adenocarcinoma (HCA-7) cells line, kindly provided by Dr Mariella Chiricolo (University of Bologna, Italy) were initially grown in standard Dulbecco's Modified Eagle's Medium (DMEM) (Sigma-Aldrich, Inc) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 0.6 mg/mL glutamine, and 200 U/mL penicillin/streptomycin (Sigma-Aldrich, Inc).

Cell cultures were replicated for subsequent experiments and maintained in water saturated atmosphere at 37°C and 5% CO~2~.

Cell viability test {#section6-2058738419855567}
-------------------

A stock solution of *T. cordifolia* was prepared dissolving 0.0167 g of dry extract in 1 mL of dimethyl sulfoxide (DMSO; Sigma-Aldrich, Inc). The pure BBR purchased from Sigma-Aldrich was re-suspended in a stock solution 5.4 mM. In both solutions, the BBR is considered to have the same concentration. Both solutions were prepared freshly.

Further dilutions were made with the culture medium to the desired concentrations just before use.

HCA-7 cells were seeded into 96-well plates at a density of 10^4^ cells per well, in 100 µL of cell culture medium, and incubated for 24 h to allow cell adherence.

Serial dilutions of *T. cordifolia* solution (30.9, 92.7, 154.5, and 309.0 µg/mL) and BBR solution (10, 30, 50, and 100 µM) were added (three wells for each concentration). The vehicle DMSO and cell culture medium alone were used as positive and negative control, respectively. After 48 h of incubation, cell viability was measured using PrestoBlue™ Reagent Protocol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Briefly, the PrestoBlue solution (10×) was added into each well containing 100 µL of treatment solution. Plates were then placed back into the incubator for 1 h, after which absorbance was measured at wavelengths of 570 nm excitation and 620 nm emission by an automated microplate reader (Sunrise™, Tecan Trading AG, Switzerland). The percentage of viable cells was determined by comparing the average absorbance in drug-treated wells with average absorbance in control wells exposed to vehicle alone. The results are presented as the mean ± standard deviation of three measures.

Cells treatment {#section7-2058738419855567}
---------------

Once determined, the most appropriate concentration for the treatments, HCA-7 cells were seeded at a density of 10^5^ cells/mL into 9 cm^2^ (3 mL) wells. Cells were washed two times with phosphate buffered serum (PBS) and incubated for 18 h at 37°C with serum-free DMEM.

After serum starvation, cells were treated with the following solutions: (a) 30.9 and 92.7 µg/mL of *T. cordifolia* methanol extract; (b) 10 and 30 µM of BBR solution, and (c) DMSO solution at the same concentration used to dissolve the extract. This treatment was the negative control.

All treatments were performed for three biological replicates in DMEM supplemented with 2% FBS, antibiotics, and amino acids.

After the end of the exposure time (24 and 48 h), cells were trypsinized and processed for RNA extraction.

RNA isolation, reverse transcription, and quantitative RT-PCR {#section8-2058738419855567}
-------------------------------------------------------------

Total RNA was isolated from cells using GenElute mammalian total RNA purification mini prep kit (Sigma-Aldrich, Inc) according to manufacturer's instructions. Total RNA concentration and quality were measured using a NanoDrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA, USA). Complementary cDNA was obtained using PrimeScript RT Master Mix (Takara Bio Inc, Shiga, Japan) starting from 500 ng of total RNA. cDNA was amplified by real-time quantitative polymerase chain reaction (PCR) using the Power SYBR^®^ Green Master Mix™ (Life Technologies, Foster City, CA, USA) and specific forward and reverse pre-designed assays (Sigma-Aldrich, Inc). The selected genes grouped by functional pathway are listed in [Table 1](#table1-2058738419855567){ref-type="table"}.

###### 

Selected genes used in real-time PCR grouped by functional pathway.

![](10.1177_2058738419855567-table1)

  Pathway                                                          Gene
  ---------------------------------------------------------------- ------------------------------------------------------
  Cell cycle                                                       ANAPC2 (anaphase-promoting complex subunit 2)
  CCNA2 (cyclin A2)                                                
  CCND1 (cyclin D1)                                                
  CCNE1 (cyclin E1)                                                
  CCNT1 (cyclin T1)                                                
  CDC6 (cell division cycle 6)                                     
  CDK4 (cyclin-dependent kinase 4)                                 
  MCM2 (minichromosome maintenance complex component 2)            
  WEE1 (WEE1 G2 checkpoint kinase)                                 
  Cell regulation                                                  ABCB5 (ATP binding cassette subfamily B member 5)
  ALDH1A1 (aldehyde dehydrogenase 1 family member A1)              
  TP63 (tumor protein p63)                                         
  MAPK1 (mitogen-activated protein kinase 1)                       
  Differentiation                                                  AKT1 (v-AKT murine thymoma viral oncogene homolog 1)
  BMP2 (bone morphogenetic protein 2)                              
  BMP7 (bone morphogenetic protein 7)                              
  EGFR (epidermal growth factor receptor)                          
  FZD7 (frizzled class receptor 7)                                 
  NOTCH1 (notch 1)                                                 
  PTP4A1 (protein tyrosine phosphatase type IVA, member 1)         
  SMAD2 (SMAD family member 2)                                     
  TGFB1 (transforming growth factor beta 1)                        
  TGFB2 (transforming growth factor beta 2)                        
  TIMP1 (TIMP metallopeptidase inhibitor 1)                        
  Epithelial--mesenchymal transition                               AHNAK (AHNAK nucleoprotein)
  BMP1 (bone morphogenetic protein 1)                              
  CALD1 (caldesmon 1)                                              
  CaMKIIG (calcium/calmodulin dependent protein kinase II gamma)   
  CDH1 (cadherin 1)                                                
  CDH2 (cadherin 2)                                                
  COL1A2 (collagen type I alpha 2)                                 
  CTNNB1 (catenin beta 1)                                          
  DSP (desmoplakin)                                                
  ITGA5 (integrin subunit alpha 5)                                 
  ROCK1 (Rho associated coiled-coil containing protein kinase 1)   
  ROCK2 (Rho associated coiled-coil containing protein kinase 2)   
  SNAI2 (snail family zinc finger 2)                               
  TCF4 (transcription factor 4)                                    
  VCAN (versican)                                                  
  VIM (vimentin)                                                   
  KRT19 (keratin 19)                                               
  OCLN (occluding)                                                 
  TSPAN13 (tetraspanin 13)                                         
  TSPAN8 (tetraspanin 8)                                           

PCR reactions were performed in 20 µL of final volume using the ABI PRISM 7500 (Applied Biosystems, Foster City, CA, USA). Each reaction contained 10 µL of 2× Power SYBR Green Master Mix, 400 nM concentration of each primer and 300 nM of cDNA.

After an initial denaturing step at 95°C for 10 min, the amplification proceeded with 40 cycles of a two-step profile of 15 s at 95°C and 60 s at 60°C. As final step, a melt curve dissociation analysis was performed. All experiments included non-template controls in order to check for the presence of contamination.

Statistical analysis {#section9-2058738419855567}
--------------------

A preliminary test was performed to select the reference gene among three housekeeping genes. RPL13 expression appeared most consistent with the amount of RNA input. Gene expression quantification was conducted with the delta/delta Ct calculation method,^[@bibr15-2058738419855567]^ and RPL13 was used as reference gene to normalize the gene expression levels.

After normalization, the delta Ct of treated cells, and control were compared by a paired sample t-test. Mean expression levels of treated cells were calculated as fold changes relative to the expression of untreated cells with the delta/delta calculation method.

Results {#section10-2058738419855567}
=======

The assay based on vital dye PrestoBlue showed that both *T. cordifolia* extract and BBR had no effect on HCA-7 cell viability at 30.9 µg/mL and 10 µM, respectively ([Figure 1(a)](#fig1-2058738419855567){ref-type="fig"} and ([b](#fig2-2058738419855567){ref-type="fig"})). An evident decrease of viability was observed at concentration starting from 92.7 µg/mL and 30 µM, respectively. The number of viable cells at these concentrations was still adequate to investigate the biologic effects of treatments, such as modulation of gene expression and cellular pathways.

![(a) Cell viability of berberine solution in HCA-7 cell line assessed by PrestoBlue reagent protocol. Cells were treated with different concentrations of drug (10, 30, 50, and 100 µM) for 48 h and (b) cell viability of *T. cordifolia* solution in HCA-7 cell line assessed by PrestoBlue Reagent Protocol. Cells were treated with various concentrations of dry extract solution (30.9, 92.7, 154.5, 309 µg/ml) for 48 h.\
Data are means ± SD.](10.1177_2058738419855567-fig1){#fig1-2058738419855567}

Gene expression of 44 genes belonging to different pathways involved in tumor progression and cell differentiation was investigated in HCA-7 cell line treated with *T. cordifolia* and BBR solutions at two different concentrations and time points. [Tables 2](#table2-2058738419855567){ref-type="table"} and [3](#table3-2058738419855567){ref-type="table"} report the effects of 24 and 48 h treatment on gene expression. Bold fonts indicate significant variation of gene expression level: fold change ⩾2 and *P* value ⩽ 0.05 for up-regulated genes, and fold change ⩽0.5 and *P* value ⩽ 0.05 for significantly down-regulated genes.

###### 

Significantly de-regulated genes after 24 h of treatment in HCA-7 cell line.

![](10.1177_2058738419855567-table2)

  Gene      Berberine 10 µM   Berberine 30 µM   *T. cordifolia* solution   *T. cordifolia* solution   Pathway                                           
  --------- ----------------- ----------------- -------------------------- -------------------------- ---------- ------------- ---------- ------------- -----------------
  ANAPC2    **0.37**          **0.007**         **0.23**                   **0.005**                  1.41       0.214         1.4        0.231         Cell cycle
  CCNA2     0.63              0.004             **0.46**                   **0.007**                  0.97       0.774         1.65       0.073         Cell cycle
  CCNE1     0.6               0.030             0.75                       0.083                      1.42       0.090         **2.03**   **0.001**     Cell cycle
  CDC6      0.9               0.532             0.78                       0.409                      **0.37**   **0.004**     0.6        0.056         Cell cycle
  CDK4      0.94              0.727             **0.48**                   **0.008**                  **2.02**   **0.010**     1.36       0.127         Cell cycle
  LGR5      1.14              0.548             **2.71**                   **0.005**                  1.33       0.218         **3.17**   **0.005**     Cell cycle
  MCM2      **0.06**          **\<0.001**       **0.06**                   **\<0.001**                **0.18**   **\<0.001**   **0.15**   **0.001**     Cell cycle
  WEE1      1.06              0.830             1.77                       0.007                      **2.57**   **0.011**     **3.03**   **0.001**     Cell cycle
  ABCB5     **0.19**          **0.013**         **4.86**                   **0.010**                  **0.25**   **0.001**     **4.15**   **0.015**     Cell regulation
  AKT1      0.83              0.326             **0.34**                   **0.003**                  1.58       0.061         1.62       0.005         Differentiation
  BMP2      0.98              0.949             0.82                       0.536                      **2.56**   **0.022**     **2.37**   **0.014**     Differentiation
  BMP7      0.6               0.025             0.69                       0.172                      1.14       0.330         **3.12**   **0.002**     Differentiation
  FZD7      **0.32**          **\<0.001**       **0.49**                   **0.005**                  1.3        0.130         1.09       0.561         Differentiation
  PTP4A1    **0.25**          **0.001**         **0.34**                   **0.003**                  1.21       0.375         1.47       0.091         Differentiation
  SMAD2     **13.8**          **\<0.001**       **12.32**                  **\<0.001**                1.3        0.278         1.99       0.001         Differentiation
  TGFB1     0.64              0.065             **0.41**                   **0.002**                  1.43       0.179         1.1        0.424         Differentiation
  TSPAN13   **0.44**          **0.016**         0.56                       0.014                      0.76       0.195         0.92       0.568         Differentiation
  TSPAN8    0.94              0.799             **2.22**                   **0.009**                  **2.21**   **0.001**     **3.06**   **0.006**     Differentiation
  CALD1     0.87              0.456             0.76                       0.075                      1.58       0.061         **2.02**   **0.002**     EMT
  CaMKII    1.3               0.011             1.26                       0.079                      **2.83**   **\<0.001**   **3.86**   **\<0.001**   EMT
  CDH2      **0.08**          **\<0.001**       **0.36**                   **0.003**                  **0.11**   **0.006**     0.66       0.078         EMT
  DSP       **0.37**          **0.015**         0.8                        0.569                      1.56       0.142         **3.68**   **0.009**     EMT
  ITGA5     **0.22**          **\<0.001**       **0.2**                    **\<0.001**                0.52       0.007         **0.48**   **0.006**     EMT
  KRT19     **0.18**          **\<0.001**       **0.18**                   **\<0.001**                0.73       0.055         0.86       0.482         EMT
  OCLN      0.89              0.686             1.34                       0.191                      **2.15**   **0.045**     1.86       0.020         EMT
  ROCK1     **0.3**           **0.005**         0.53                       \<0.001                    1.06       0.611         1.96       0.002         EMT
  SNAI2     **0.23**          **0.005**         0.73                       0.355                      0.58       0.061         1.86       0.113         EMT
  VCAN      1.14              0.631             **2.99**                   **\<0.001**                1.25       0.425         **2.19**   **0.046**     EMT
  VIM       0.62              0.034             **2.17**                   **0.007**                  1.39       0.098         **2.15**   **0.007**     EMT

EMT: epithelial--mesenchymal transition.

In bold significant gene expression level.

Significantly up-regulated gene: fold change ⩾2 and *P* value ⩽ 0.05.

Significantly down-regulated gene: fold change ⩽0.5 and *P* value ⩽ 0.05.

###### 

Significantly de-regulated genes after 48 h of treatment in HCA-7 cell line.

![](10.1177_2058738419855567-table3)

  Gene      Berberine 10 µM   Berberine 30 µM   *T. cordifolia* solution   *T. cordifolia* solution   Pathway                                           
  --------- ----------------- ----------------- -------------------------- -------------------------- ---------- ------------- ---------- ------------- -----------------
  ANAPC2    **0.23**          **0.001**         **0.3**                    **0.021**                  **0.32**   **0.010**     **0.32**   **0.024**     Cell cycle
  CCNA2     **0.07**          **\<0.001**       **0.05**                   **\<0.001**                **0.03**   **\<0.001**   **0.04**   **\<0.001**   Cell cycle
  BMP2      0.8               0.290             **0.3**                    **0.014**                  0.73       0.358         **0.3**    **0.010**     Differentiation
  BMP7      0.53              0.002             0.55                       0.007                      **0.33**   **\<0.001**   **0.22**   **\<0.001**   Differentiation
  PTP4A1    **0.2**           **\<0.001**       **0.27**                   **0.020**                  **0.28**   **0.002**     **0.32**   **0.001**     Differentiation
  TGFB1     0.53              0.006             **0.3**                    **\<0.001**                1.13       0.445         0.71       0.125         Differentiation
  TSPAN13   0.63              0.026             **0.37**                   **0.001**                  0.67       0.050         **0.46**   **0.003**     Differentiation
  CALD1     0.61              0.005             **0.27**                   **0.005**                  0.74       0.038         0.51       0.007         EMT
  CaMKII    **0.37**          **\<0.001**       **0.26**                   **0.002**                  **0.33**   **\<0.001**   **0.24**   **\<0.001**   EMT
  CDH2      1.93              0.028             1.24                       0.283                      **0.37**   **0.005**     0.52       0.034         EMT
  ITGA5     **0.13**          **\<0.001**       **0.18**                   **0.001**                  **0.12**   **\<0.001**   **0.14**   **\<0.001**   EMT
  SNAI2     0.79              0.177             **0.44**                   **0.008**                  0.54       0.014         **0.22**   **\<0.001**   EMT
  TIMP1     0.64              0.156             **0.22**                   **0.001**                  0.75       0.187         **0.38**   **0.005**     EMT

EMT: epithelial--mesenchymal transition.

In bold significant gene expression level.

Significantly up-regulated gene: fold change ⩾2 and *P* value ⩽ 0.05.

Significantly down-regulated gene: fold change ⩽0.5 and *P* value ⩽ 0.05.

The most relevant effects were observed after 48 h ([Figures 2](#fig2-2058738419855567){ref-type="fig"} and [3](#fig3-2058738419855567){ref-type="fig"}).

![Gene expression profile of HCA-7-treated cells (30.9 µg/mL of *T. cordifolia* and 10 µM of berberine) *vs* control at 48 h.](10.1177_2058738419855567-fig2){#fig2-2058738419855567}

![Gene expression profile of HCA-7-treated cells (92.7 µg/mL of *T. cordifolia* and 30 µM of berberine) *vs* control at 48 h.](10.1177_2058738419855567-fig3){#fig3-2058738419855567}

A total of 13 genes of the 44 studied were significantly over- and down-regulated and belong essentially to three pathways: cell cycle and regulation, differentiation, epithelial--mesenchymal transition (EMT).

Interestingly, both the plant extract and the BBR showed the same effects on the expression profiling of treated cells. In particular, the genes that maintained the same expression trend following all the treatments were ANAPC2 and CCNA2, involved in cycle regulation; BMP7 and PTP4A1 belonging to cell differentiation pathway; CaMKII and ITGA5 involved in EMT. This set of genes was significantly down-regulated in treated cells with respect to the control.

Discussion {#section11-2058738419855567}
==========

Plant-based drug discovery has played an important role in the development of anticancer drugs currently in clinical use.^[@bibr1-2058738419855567]^

Several medicinal plants used in different traditional medicine systems showed anti-tumorigenic activity.^[@bibr16-2058738419855567][@bibr17-2058738419855567]--[@bibr18-2058738419855567]^ Specifically, plants containing BBR might be promising suppressing agents.

In this investigation, we observed the effect of *T. cordifolia* extract on the HCA-7 colon cancer cell line as compared with purified BBR. The content of BBR in the extract of *T. cordifolia* was evaluated by LC-MS analysis in order to treat the cells with comparable concentration of BBR. Two different concentrations of BBR were chosen for the assay based on the result of a viability test.

Considering the quality of the mRNA extracted from treated cells the highest concentration of *T. cordifolia* (92.7 µg/mL) and of BBR used (30 µM) was supposed not lethal but sufficient to induce a significant response. In fact, at the second time point (48 h from the treatment), a similar trend of down regulation of selected genes was confirmed both for the treatment with *T. cordifolia* extract and for the one with pure BBR for the two different concentrations (30.9 µg/mL, 92.7 µg/mL, and 10 µM, 30 µM, respectively).

These observations let hypothesize the involvement of BBR in the activity showed by the *T. cordifolia*.

The transcriptional level of 44 genes known to be involved in specific pathways such as cell cycle, differentiation, or EMT was monitored.

Among the genes modulated by the treatments, a couple of genes of cell cycle pathway resulted significantly down-regulated: ANAPC2 and CCNA2. The first one codes for a subunit of the anaphase-promoting complex (APC), involved in the progression of the cell cycle. Recently, the chemopreventive and chemotherapeutic potential of curcumin, contained in the Asian spice *Curcuma longa*, has been related to APC inhibition and apoptosis induction.^[@bibr19-2058738419855567]^ The gene CCNA2 codes for cyclin A2, that is able to bind to CDK2 and plays critical roles in cells proliferation; the over expression of CCNA2 has been linked to colorectal carcinogenesis and tumor invasion.^[@bibr20-2058738419855567]^

Alteration of epithelial cells homeostasis and acquisition of migratory mesenchymal phenotype are crucial steps in progression of epithelial cancers. In this study, it was shown that the expression level of several genes involved in differentiation and EMT was modulated by *T. cordifolia* and BBR treatments.

Bone morphogenetic proteins (BMPs) are responsible for tumorigenesis and metastatic progression of many types of cancer, inducing EMT and activating the tumorigenic potential of cancer stem cells in human colorectal cancer.^[@bibr21-2058738419855567]^ The up-regulation of BMP7 in colorectal cancer determines a poor prognosis caused by the increased aggressiveness of the tumor and onset of liver metastases.^[@bibr22-2058738419855567]^ We found significantly down-regulated both BMP2 and BMP7 in our system.

The expression of PTP4A1 was found four times lower in treated cells compared to control. Its product is localized preferentially in the cytoplasm of colon adenocarcinoma cells, endothelial cells, and smooth muscle cells in proximity of vessels surrounding lymph node metastases.^[@bibr23-2058738419855567],[@bibr24-2058738419855567]^

Another down-regulated gene in treated cells was TSPAN13 that encodes a transmembrane protein involved in cell motility. Up-regulation of this gene has been reported at the progression stage of many cancers such as ovarian adenocarcinoma, breast cancer, bladder carcinoma, and acute lymphoblastic leukemia.^[@bibr25-2058738419855567]^

Two Ca^2+^/calmodulin-dependent proteins, CALD1 and CAMKIIG, were down-regulated in HCA-7 cells after exposure to *T. cordifolia* and BBR. CALD1 is involved in migration, invasion, and proliferation of many tumors, including colorectal cancer. Overexpression of CALD1 in peritoneal cancer cells has been associated to reduced tumor prognosis,^[@bibr19-2058738419855567]^ while inhibition of CAMKIIG through synthetic compounds suppressed the growth of cancer cells, inducing apoptosis.^[@bibr26-2058738419855567]^

TGFB1 increases the invasive properties of colon cancer cells increasing the expression of CDH2 coding for the N-cadherin, located at the tips of myofibroblast filopodia.^[@bibr27-2058738419855567]^ In our investigation, CDH2 was significantly down-regulated at the higher concentration of both treatments.

The integrin α5, ITGA5, was strongly down-regulated in treated cells compared to control with an expression decreased by 10 times. The altered expression of ITGA5 during tumor progression has been largely demonstrated in colon cancer cells line with highly invasive potential.^[@bibr28-2058738419855567]^

Two genes involved in EMT and down-regulated only at the higher concentration of *T. cordifolia* and BBR were SNAI2 and TIMP1. SNAI2 mediates resistance to 5-fluorouracil chemotherapy in colorectal cancer, representing a new therapeutic target to improve current treatment strategies.^[@bibr29-2058738419855567]^ Serum and tissue levels of TIMP1 are increased in patients with colon cancer. TIMP1 has anti-apoptotic role through the pathway of Bcl-2, stimulating cell growth and promoting the migration and metastatic invasion.^[@bibr30-2058738419855567]^

Conclusion {#section12-2058738419855567}
==========

Our study demonstrated that extract of *T. cordifolia* is able to inhibit the expression of several genes involved in colon cancer development and progression. The effects of *T. cordifolia* treatment were well resembled by pure BBR; this evidence suggested that the main effects of *T. cordifolia* were mediated by BBR. The ability to strongly reduce expression of genes involved in proliferation, differentiation, cell motility, and EMT suggests further research efforts to explore the use of these substances as chemotherapeutic agent in colorectal cancer.
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